The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Abstract
Purpose: The benefit of adjuvant therapy (AT) for biliary tract cancer (BTC) is unclear, with conflicting results from nonrandomized studies. We report a systematic review and meta-analysis to determine the impact of AT on survival. Methods: Studies published between 1960 and November 2010, which evaluated adjuvant chemotherapy (CT), radiotherapy (RT), or both (CRT) compared with curative-intent surgery alone for resected BTC were included. Only tumors of the gallbladder and bile ducts were assessed. Published data were extracted and computed into odds ratios (ORs) for death at 5 years. Subgroup analyses of benefit based on lymph node (LN) or resection margin positivity (R1) were prespecified. Data were weighted by generic inverse variance and pooled using random-effect modeling. Results: Twenty studies involving 6,712 patients were analyzed. There was a nonsignificant improvement in overall survival with any AT compared with surgery alone (pooled OR, 0.74; P = .06). There was no difference between gallbladder and bile duct tumors (P = .68). The association was significant when the two registry analyses were excluded. Those receiving CT or CRT derived statistically greater benefit than RT alone (OR, 0.39, 0.61, and 0.98, respectively; P = .02). The greatest benefit for AT was in those with LN-positive disease (OR, 0.49; P = .004) and R1 disease (OR, 0.36; P = .002). Conclusion: This analysis supports AT for BTC. Prospective randomized trials are needed to provide better rationale for this commonly used strategy. On the basis of our data, such trials could involve two active comparators rather than a no-treatment arm among patients with LN-positive or R1 disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
(2012) · Hepatogastroenterology · doi:10.5754/hge12183 · Cited by 1,625
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1275 · Cited by 1,397
Systematic reviews of evaluations of diagnostic and screening tests
Deeks, J. J. (2001) · BMJ · doi:10.1136/bmj.323.7305.157 · Cited by 1,340
de Groen, P. C., Gores, G. J., LaRusso, N. F., Gunderson, L. L., & Nagorney, D. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411807 · Cited by 955
Systematic reviews of evaluations of diagnostic and screening tests
(2001) · Europe PMC (PubMed Central) · Cited by 850
Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Takada, T., Amano, H., Yasuda, H., Nimura, Y., Matsushiro, T., Kato, H., Nagakawa, T., & Nakayama, T. (2002) · Cancer · doi:10.1002/cncr.10831 · Cited by 631
Jarnagin, W. R., Ruo, L., Little, S. A., Klimstra, D., D'Angelica, M., DeMatteo, R. P., Wagman, R., Blumgart, L. H., & Fong, Y. (2003) · Cancer · doi:10.1002/cncr.11699 · Cited by 454
Periampullary Adenocarcinoma: Analysis of 5-Year Survivors
Yeo, C. J., Sohn, T. A., Cameron, J. L., Hruban, R. H., Lillemoe, K. D., & Pitt, H. A. (1998) · Annals of Surgery · doi:10.1097/00000658-199806000-00005 · Cited by 390
Analysing and Presenting Results
Macaskill, P., Gatsonis, C., Deeks, J. J., Harbord, R., & Takwoingi, Y. (2010) · Bristol Research (University of Bristol) · Cited by 337
Diagnosis and Treatment of Cholangiocarcinoma
Anderson, C. D., Wright Pinson, C., Berlin, J., & Chari, R. S. (2004) · The Oncologist · doi:10.1634/theoncologist.9-1-43 · Cited by 332
Perihilar Cholangiocarcinoma Postoperative Radiotherapy Does Not Improve Survival
Pitt, H. A., Nakeeb, A., Abrams, R. A., Coleman, J., Piantadosi, S., Yeo, C. J., Lillemoe, K. D., & Cameron, J. L. (1995) · Annals of Surgery · doi:10.1097/00000658-199506000-00017 · Cited by 299
Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma
McMasters, K. M., Tuttle, T. M., Leach, S. D., Rich, T., Cleary, K. R., Evans, D. B., & Curley, S. A. (1997) · The American Journal of Surgery · doi:10.1016/s0002-9610(97)00203-1 · Cited by 220
Surgical Resection of Hilar Cholangiocarcinoma: Analysis of Survival and Postoperative Complications
Hasegawa, S., Ikai, I., Fujii, H., Hatano, E., & Shimahara, Y. (2007) · World Journal of Surgery · doi:10.1007/s00268-007-9001-y · Cited by 220
Todoroki, T., Ohara, K., Kawamoto, T., Koike, N., Yoshida, S., Kashiwagi, H., Otsuka, M., & Fukao, K. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00472-1 · Cited by 194
Results of Postoperative Radiotherapy for Resectable Hilar Cholangiocarcinoma
Gerhards, M. F., van Gulik, T. M., González, D. G., Rauws, E. A. J., & Gouma, D. J. (2003) · World Journal of Surgery · doi:10.1007/s00268-002-6434-1 · Cited by 179
Adjuvant Therapy for Gallbladder Carcinoma: The Mayo Clinic Experience
Gold, D. G., Miller, R. C., Haddock, M. G., Gunderson, L. L., Quevedo, F., Donohue, J. H., Bhatia, S., & Nagorney, D. M. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.052 · Cited by 143
Adjuvant Concurrent Chemoradiation for Adenocarcinoma of the Distal Common Bile Duct
Hughes, M. A., Frassica, D. A., Yeo, C. J., Riall, T. S., Lillemoe, K. D., Cameron, J. L., Donehower, R. C., Laheru, D. A., Hruban, R. H., & Abrams, R. A. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.11.048 · Cited by 134
Vern-Gross, T. Z., Shivnani, A. T., Chen, K., Lee, C. M., Tward, J. D., Macdonald, O. K., Crane, C. H., Talamonti, M., Munoz, L. L., & Small, W. C. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.05.001 · Cited by 74
Cholangiocarcinoma: The Impact of Tumor Location and Treatment Strategy on Outcome
Heron, D. E., Stein, D. E., Eschelman, D. J., et al. (2003) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000026833.73428.1f · Cited by 69
Itoh, H., Nishijima, K., Kurosaka, Y., et al. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-3040-8 · Cited by 57
Cited by
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30915-x · Cited by 1,273
Valle, J. W., Kelley, R. K., Nervi, B., Oh, D.-Y., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,043
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Bridgewater, J., Edeline, J., Kelley, R. K., Klümpen, H. J., Malka, D., Primrose, J. N., Rimassa, L., Stenzinger, A., Valle, J. W., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.506 · Cited by 718
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Valle, J. W., Borbath, I., Khan, S. A., Huguet, F., Gruenberger, T., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw324 · Cited by 675
Metadata
- Authors
- Horgan, A. M., Amir, E., Walter, T., & Knox, J. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-06-01
- Volume
- 30
- Issue
- 16
- Pages
- 1934-1940
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148899606
- Cited by
- 716
- References
- 23
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.